A 45-year-old with asthma receives three albuterol-ipratropium treatments for wheezing with peak flow 55% predicted. Wheeze persists, accessory use remains, but SpO2 is 94% on room air and speech is full sentences. Which therapy decision best applies continue-modify-discontinue judgment for bronchodilator treatment?

Persistent wheeze, accessory use and peak flow 55% predicted after three albuterol-ipratropium treatments indicate incomplete response, so correct judgment continues scheduled short-acting bronchodilators for ongoing bronchoconstriction, modifies care by adding systemic steroids for inflammation bronchodilators cannot treat, and reassesses airflow plus work of breathing serially to guide escalation or step-down. Continuing bronchodilators with steroids but monitoring only oximetry and speech without repeated peak flow fails on assessment concept because SpO2 94% and full sentences reflect gas exchange and compensation, not obstruction, and cannot track residual limitation or treatment trend. Giving steroids then observing without further scheduled bronchodilators fails on continuation concept because steroids act over hours and provide no acute bronchodilation, leaving active wheeze and accessory use untreated despite reassuring vitals. Continuing bronchodilators with serial reassessment but withholding steroids because oxygen and speech improved fails on modification concept because incomplete response after repeated bronchodilators signals steroid-responsive inflammation requiring early systemic therapy to prevent relapse and progression. Exam caveat is that adequate oxygenation and fluent speech do not equal recovery when objective airflow and increased work persist. Practical check is to trend peak flow, wheeze, accessory use, respiratory rate, speech and SpO2 together with steroid timing to decide to continue, escalate, or discontinue.